Compounds > linogliride
Page last updated: 2024-08-01 23:28:25

linogliride

Description

linogliride: structure given in first source [MeSH]

Cross-References

ID SourceID
PubMed CID6536869
CHEMBL ID40356
MeSH IDM0129779

Synonyms (21)

Synonym
linogliride
75358-37-1
linogliride (usan/inn)
D04739
CHEMBL40356
mcn 3935
(ne)-n-(1-methylpyrrolidin-2-ylidene)-n'-phenylmorpholine-4-carboximidamide
linogliridum [latin]
7e521jyj4x ,
linoglirida
n-(1-methyl-2-pyrrolidinylidene)-n'-phenyl-4-morpholinecarboxamidine
linogliridum
unii-7e521jyj4x
linoglirida [spanish]
4-morpholinecarboximidamide, n-(1-methyl-2-pyrrolidinylidene)-n'-phenyl-
linogliride [usan:inn]
linogliride [inn]
linogliride [usan]
DTXSID201024552
n-(1-methyl-2-pyrrolidinylidene)-n'-phenyl-4-morpholinecarboximidamide
AKOS040747103

Bioassays (2)

Assay IDTitleYearJournalArticle
AID194310Mean maximum percent lowering of glucose at a single dose of 10 mg/kg, subcutaneously using rat oral glucose tolerance test.1993Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
ISSN: 0022-2623		A novel series of N-(1-aminoalkylidene)carboximidamides as potential hypoglycemic agents.
AID177194Effective dose to produce a 30% maximum decrease of glucose from control1993Journal of medicinal chemistry, May-28, Volume: 36, Issue:11
ISSN: 0022-2623		A novel series of N-(1-aminoalkylidene)carboximidamides as potential hypoglycemic agents.

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (33.33)18.7374
1990's7 (58.33)18.2507
2000's0 (0.00)29.6817
2010's1 (8.33)24.3611
2020's0 (0.00)2.80

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (8.33%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other11 (91.67%)84.16%
SubstanceStudiesClassesRolesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
4-aminopyridine
1
aminopyridine;
aromatic amine		avicide;
orphan drug;
potassium channel blocker		1995199529.0low001000
chlorpropamide
1
monochlorobenzenes;
N-sulfonylurea		hypoglycemic agent;
insulin secretagogue		1989198935.0low010000
gliclazide
1
N-sulfonylureahypoglycemic agent;
insulin secretagogue;
radical scavenger		1990199034.0low001000
glimepiride
1
sulfonamide1990199034.0low001000
glyburide
3
monochlorobenzenes;
N-sulfonylurea		anti-arrhythmia drug;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor;
hypoglycemic agent		1990199929.3medium003000
tetraethylammonium
2
quaternary ammonium ion1995199927.0low002000
tolbutamide
2
N-sulfonylureahuman metabolite;
hypoglycemic agent;
insulin secretagogue;
potassium channel blocker		1991199133.0low002000
cyclohexanol
1
cyclohexanols;
secondary alcohol		solvent1990199034.0low001000
tetradecanoylphorbol acetate
1
acetate ester;
diester;
phorbol ester;
tertiary alpha-hydroxy ketone;
tetradecanoate ester		antineoplastic agent;
apoptosis inducer;
carcinogenic agent;
mitogen;
plant metabolite;
protein kinase C agonist;
reactive oxygen species generator		1987198737.0low010000
pirogliride
1
1990199034.0medium001000
midaglizole
1
1990199034.0low001000
deoxyglucose
1
1987198737.0low010000
quinidine
2
cinchona alkaloidalpha-adrenergic antagonist;
anti-arrhythmia drug;
antimalarial;
drug allergen;
EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor;
EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor;
muscarinic antagonist;
P450 inhibitor;
potassium channel blocker;
sodium channel blocker		1995199927.0low002000
ao 128
1
organic molecular entity1990199034.0low001000
glucagon
1
peptide hormone1991199133.0low001000
c-peptide
1
1987198737.0low110000
ConditionIndicatedStudiesFirst YearLast YearAverage AgeRelationship StrengthTrialspre-19901990's2000's2010'spost-2020
Breast Cancer0
2
1995199927.0high002000
Breast Neoplasms0
2
1995199927.0high002000
Diabetes Mellitus0
1
1990199034.0medium001000
Diabetes Mellitus, Adult-Onset0
1
1987198737.0medium110000
Diabetes Mellitus, Type 20
1
1987198737.0medium110000

Dosage (1)

ArticleYear
The preparation and evaluation of salt forms of linogliride with reduced solubilities as candidates for extended release.
Drug development and industrial pharmacy, , Volume: 43, Issue:3		2017